These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20547180)

  • 21. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
    Phillips DR; Hay P
    J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
    Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
    Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
    Sattler FR
    Top HIV Med; 2008; 16(4):127-33. PubMed ID: 18838747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
    Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
    Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lipodystrophy syndrome. Therapeutic progress is still pending].
    Weber K; Heiken H; Stoll M; Schmidt RE; Behrens G
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():28-32. PubMed ID: 15011581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV--associated lipodystrophy in children.
    Krause JC; Toye MP; Stechenberg BW; Reiter EO; Allen HF
    Pediatr Endocrinol Rev; 2005 Sep; 3(1):45-51. PubMed ID: 16369213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HAART-associated body habitus and metabolic changes, Part 1.
    Liss M; Boyle BA
    AIDS Read; 2000 Nov; 10(11):622, 629-31. PubMed ID: 11186180
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 36. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
    Hirsch HH; Battegay M
    Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [No improvement of lipodystrophy syndrome in an HIV-infected patient].
    Lanzafame M; Faggian F; Lattuada E; Antolini D; Concia E
    Recenti Prog Med; 2004 Jun; 95(6):312-3. PubMed ID: 15248414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
    McComsey G; Maa JF
    AIDS Read; 2003 Nov; 13(11):539-42, 559. PubMed ID: 14649623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity.
    Villarroya F; Domingo P; Giralt M
    Trends Pharmacol Sci; 2005 Feb; 26(2):88-93. PubMed ID: 15681026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.